A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of OnabotulinumtoxinA for the Treatment of Upper Limb Essential Tremor: ELATE Trial
Objective: Here, we present the eligibility criteria and study design of ELATE, a Phase 2b clinical trial evaluating the safety and efficacy of onabotA compared…Botulinum Toxin A Usage in Movement Disorder Division: A Retrospective Chart Review
Objective: To evaluate the cost-effectiveness of Botulinum Toxin A in our movement disorder division. Background: Botulinum Toxin A is an FDA-approved treatment for various medical…Real-World Retrospective Safety Analysis in Patients Treated With OnabotulinumtoxinA for Multiple Therapeutic Indications Over Repeat Treatment Periods
Objective: To evaluate the real-world safety of onabotulinumtoxinA (onabotA) use over repeat treatment periods (TPs) in patients (pts) with concomitant multiple therapeutic indications. Background: In…Predictors of Response to Botulinum Toxin Treatment in Patients With Hemifacial Spasm:A Prospective Study
Objective: To study the predictors of Good and Bad outcome and the impact on quality of life of patients with HFS following Botulinum toxin treatment.…Patient Characteristics and Real-World Use of Botulinum Toxins for Treatment of Chronic Sialorrhea
Objective: We aimed to describe the demographics, clinical characteristics, and treatment patterns among patients with evidence of chronic sialorrhea. Background: Patients with neurological impairment may…Refining Aesthetic Eyebrows: Botulinum Toxin Injection for Hemifacial Spasm.
Objective: To investigate the efficacy of botulinum toxin injection (BoNTA) in correcting eyebrow asymmetry in patients with hemifacial spasms (HFS). Background: HFS typically affects women…Incobotulinumtoxin A to Treat Sialorrhea in Parkinson’s Disease: a Real-life Study: 5-year Interim Results
Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea (10 injection cycles (IC)). Background:…Medication Refractory Restless Legs Syndrome: Real-World Experience
Objective: To identify demographic or clinical factors predictive of refractory cases. Background: Restless Legs Syndrome (RLS), impacting 5-13% of the US population, poses challenges in…Real-world retrospective safety analysis of onabotulinumtoxinA for the treatment of patients with concurrent cervical dystonia and chronic migraine
Objective: To assess the real-world safety of onabotulinumtoxinA (onabotA) for the concomitant treatment of cervical dystonia (CD) and chronic migraine (CM). Background: In the United…Hemifacial Spasm: Recent experience in a movement disorders reference center in Chile
Objective: To analyze the demographic characteristics of patients with HFS and their response to different BoNT at the center for movement disorders CETRAM in Santiago,…
- 1
- 2
- 3
- …
- 12
- Next Page »